Kristie L. Kahl

Articles

PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer

February 12th 2021

February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8th 2021

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

Pembrolizumab Continues to Improve Survival in PD-L1–Positive Advanced NSCLC

January 28th 2021

January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.

Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC

January 16th 2021

January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.

Behavioral Interventions Reduce Depressive Symptoms in Young Breast Cancer Survivors

December 10th 2020

December 10, 2020 - Mindfulness meditation and survivorship education classes reduced depressive symptoms in younger women treated for breast cancer.

Women Who Undergo Mastectomy with Reconstruction At Higher Risk for Chronic Controlled Substance Use

December 9th 2020

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma

December 7th 2020

December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC

September 21st 2020

Treatment with cabozantinib in combination with atezolizumab demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma.

Novel BiTE Immuno-Oncology Therapy Appears Safe with Preliminary Efficacy in mCRPC

September 21st 2020

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Updated Findings Show Olaparib Prolongs OS in Men with mCRPC

September 20th 2020

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

AMG 330 Shows Promise in Treating Relapsed/Refractory AML

May 30th 2020

Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.

Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC

May 30th 2020

Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.

Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC

May 29th 2020

Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.

Tivozanib's Safety Profile Linked With Advantage in Advanced RCC Treatment

May 20th 2020

Brian I. Rini, MD, speaks about the TIVO-3 trial and how its results could provide patients with another “weapon in this disease.”

Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer

May 13th 2020

Integration of a comprehensive geriatric assessment with geriatrician-led management care improved health-related quality of life, unplanned hospital admissions, and treatment discontinuation among older adults undergoing systemic therapy for their cancer.

Maintenance Therapy with Olaparib Extends Survival in Relapsed, BRCA+ Ovarian Cancer

May 13th 2020

Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.

All Stakeholders Are Responsible for Genetic Testing

March 7th 2020

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer

December 11th 2019

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.

Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL

June 4th 2019

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

Enfortumab Vedotin Produces Responses in Patients With Advanced Urothelial Carcinoma

June 3rd 2019

Enfortumab vedotin induced responses in 44% of patients with locally advanced or metastatic urothelial cancer, including 12% experiencing a complete response to treatment.